Consensus for FY24 EPS is $1.65. Still sees FY24 revenue $2.7B-$2.8B, consensus $2.77B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Reports Record Financial Results for the First Quarter 2024
- BioMarin price target raised to $110 from $100 at Cantor Fitzgerald
- Biomarin Pharmaceutical Inc. (BMRN) Q1 Earnings Cheat Sheet
- BioMarin participates in a conference call with JPMorgan.
- BioMarin presents new data for Voxzogo in achondroplasia and achondroplasia
